CHINA PHARMA HOLDINGS Business Summary

China Pharma Holdings, Inc. (CPHI) generates revenue primarily through the development, manufacture, and commercialization of generic and specialty pharmaceutical products within the People’s Republic of China. The company’s business model is centered on a high-volume transaction strategy, leveraging a nationwide distribution network to supply hospitals and pharmacies with treatments for high-incidence conditions. Its primary business segments are categorized by therapeutic area, including cardiovascular, central nervous system (CNS), infectious, and digestive diseases. Recently, the company has pivoted toward medical technology with the 2025 launch of a therapeutic device for Dry Eye Disease (DED) to offset declining drug sales. CPHI operates as a micro-cap player in a fragmented market, competing directly with firms such as China SXT Pharmaceuticals, Inc., Universe Pharmaceuticals Inc., and Zai Lab Ltd. Relative to these peers, CPHI occupies a niche as a legacy manufacturer currently undergoing a strategic turnaround focused on higher-margin medical devices. The leadership team is anchored by founder Zhilin Li, who serves in the consolidated roles of Chairman, President, Chief Executive Officer, and Interim Chief Financial Officer. Ms. Li brings a deep technical pedigree to the firm, having previously served as the President of the Haikou Bio-Engineering Institute and Vice President of the Sichuan Institute of Biology. The company’s governance is overseen by a seasoned Board of Directors, which includes independent directors Gene Michael Bennett, Yingwen Zhang, and Baowen Dong, all of whom were re-elected in late 2025 to steer the company through its current capital restructuring and reverse stock split initiatives. Ownership remains heavily concentrated among insiders, with Zhilin Li maintaining the largest individual stake, reflecting a founder-led management structure with significant skin in the game.